Reproduction/Androgen Disorders News

BOSTON — Women exposed to a class of endocrine-disrupting chemicals known as PFAS may be more likely to struggle with breastfeeding, whereas the health effects of infant exposure to PFAS via breastmilk remain unknown, a speaker said.

BOSTON — Evidence suggests hyperandrogenism is associated with changes in the gut microbiome in women with polycystic ovary syndrome and the gut microbiome may play a causal role in PCOS metabolic dysregulation, according to a speaker.

BOSTON — Midlife women reporting bothersome hot flashes are more likely to receive a diagnosis of metabolic dysfunction-associated steatotic liver disease regardless of hormone therapy use, according to a speaker.

PHILADELPHIA — Consistently missed periods brought on by intense exercise, disordered eating or stress in young women can lead to multiple consequences, including endothelial dysfunction and increased CVD risk, according to a speaker.

BOSTON — People with primary ovarian insufficiency have higher risk for breast cancer and borderline increased risk for ovarian cancer compared with the general population, and risks for some cancers extend to their relatives, data show.

Most high and moderate risk factors for preeclampsia have increased from 2010 to 2021 in the U.S., according to a research letter published in JAMA.

BOSTON — Pregnant and reproductive-aged women have had recent declines in exposure to most endocrine-disrupting chemicals, though women with a lower socioeconomic status are exposed to higher chemical levels, according to a speaker.

Regardless of socioeconomic status, menopause symptom severity was associated with race and ethnicity, highlighting differences in symptom experiences, according to study results published in Menopause.

BOSTON — In this video exclusive, Andrea Dunaif, MD, discusses some of the latest research on polycystic ovary syndrome featured at the ENDO 2024.

BOSTON — In a phase 2b trial, a hormonal contraceptive gel for use by men worked faster than expected, suppressing sperm count to effective levels by week 8 of use, making it an “attractive” product, according to a speaker at ENDO 2024.